Skip to main content
View Cart

Books in Pharmacology

Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.

  • A Pharmacology Primer

    Theory, Application and Methods
    • 3rd Edition
    • February 7, 2009
    • Terry P. Kenakin
    • English
    This successful guide assists scientists trained in molecular biology and related fields who now need to know the basic theories, principles and practical applications of pharmacology. This latest edition continues the tradition of better preparing researchers in the basics of pharmacology. With expanded hands-on exercises and the addition of Pharmacokinetics coverage, new human interest material including historical facts in pharmacology and a new section on therapeutics that will help readers identify with diseases and drug treatments.The ideal book for researchers in drug discovery who have seen their role shift from "individual" to "team player" where that team includes chemists, biologists, and others with strong, but varied, science backgrounds who must now work together toward their common pharmacology goal. At GlaxoSmithKline, a pharmaceuticals world-leader, Terry Kenakin regularly teaches a course for their research scientists and has drawn on his experience to create a pharmacology primer.

  • Meyler's Side Effects of Endocrine and Metabolic Drugs

    • 1st Edition
    • January 20, 2009
    • Jeffrey K. Aronson
    • English
    Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Endocrine and metabolic diseases are common, includes diseases such as diabetes, thyroid disease, and obesity. Endocrinologists, including diabetes professionals, internal medicine and primary care practitioners, obstetricians and gynecologists, and others will find this book useful when treating endocrine or metabolic diseases.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler’s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of endocrine and metabolics mediations.

  • Meyler's Side Effects of Cardiovascular Drugs

    • 1st Edition
    • January 20, 2009
    • Jeffrey K. Aronson
    • English
    Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment of heart failure, angina, angina pectoris, and cardiac arrhythmia and enable practitioners to prescribe preventative treatments with medications such as blood pressure reducers, aspirin, and cholesterol-lowering drugs, as well as drugs used for more aggressive therapy.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler’s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of cardiovascular mediations.

  • Developing Solid Oral Dosage Forms

    Pharmaceutical Theory and Practice
    • 1st Edition
    • December 19, 2008
    • Yihong Qiu + 4 more
    • English
    Developing Solid Oral Dosage Forms is intended for pharmaceutical professionals engaged in research and development of oral dosage forms. It covers essential principles of physical pharmacy, biopharmaceutics and industrial pharmacy as well as various aspects of state-of-the-art techniques and approaches in pharmaceutical sciences and technologies along with examples and/or case studies in product development. The objective of this book is to offer updated (or current) knowledge and skills required for rational oral product design and development. The specific goals are to provide readers with: Basics of modern theories of physical pharmacy, biopharmaceutics and industrial pharmacy and their applications throughout the entire process of research and development of oral dosage forms Tools and approaches of preformulation investigation, formulation/process design, characterization and scale-up in pharmaceutical sciences and technologies New developments, challenges, trends, opportunities, intellectual property issues and regulations in solid product development

  • Clinical and Translational Science

    Principles of Human Research
    • 1st Edition
    • December 15, 2008
    • David Robertson + 1 more
    • English
    Clinical or translational science is the field of study devoted to investigating human health and disease, interventions and outcomes for the purposes of developing new treatment approaches, devices, and modalities to improve health. New molecular tools and diagnostic technologies based on clinical and translational research have lead to a better understanding of human disease and the application of new therapeutics for enhanced health. Clinical and Translational Science is designed as the most authoritative and modern resource for the broad range of investigators in various medical specialties taking on the challenge of clinical research. Prepared with an international perspective, this resource begins with experimental design and investigative tools to set the scene for readers. It then moves on to human genetics and pharmacology with a focus on statistics, epidemiology, genomic information, drug discovery and development, and clinical trials. Finally, it turns to legal, social, and ethical issues of clinical research concluding with a discussion of future prospects to provide readers with a comprehensive view of the this developing area of science.

  • Animal and Translational Models for CNS Drug Discovery

    • 1st Edition
    • October 21, 2008
    • Robert A. McArthur + 1 more
    • English
    Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

  • Meyler's Side Effects of Psychiatric Drugs

    • 1st Edition
    • October 10, 2008
    • Jeffrey K. Aronson
    • English
    Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. The unwarranted effects of medications used in psychiatry can adversely affect a treatment plan. This book is critical in helping psychiatrists and mental health professionals assess the adverse effects of drugs such as antidepressants, mood stabilizers, hypnosedatives, and antipsychotic drugs.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler’s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of psychiatric mediations.

  • Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

    • 1st Edition
    • October 6, 2008
    • Robert A. McArthur + 1 more
    • English
    Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually.

  • Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

    • 1st Edition
    • October 6, 2008
    • Robert A. McArthur + 1 more
    • English
    Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

  • Meyler's Side Effects of Herbal Medicines

    • 1st Edition
    • September 23, 2008
    • Jeffrey K. Aronson
    • English
    Meyler's Side Effects of Herbal Medicines, named to Doody's Core Titles for 2013, is a derivatrive work based on the acclaimed Meyler’s Side Effect of Drugs, Fifteenth Edition. This book summarizes the adverse effects of a large range of herbal medicines and the active ingredients that they contain. It includes extensive lists of the families of plants that are used as herbal medicines, including the Latin names of genera and species as well as the common names of individual plants. It features not only herbal medicines but information on important compounds such as tropane alkaloids, cardiac glycosides, nicotine, and pyrolizidine alkaloids. The book is divided into three separate sections: Family – Each monograph is organized under a family of plants (for example, Liliaceae) Genera – The various genera that are included under the family name are tabulated (for example, the family Liliaceae contains 94 genera) Species – In each monograph, some species are dealt with separately (for example, in Liliaceae, four species are included under their Latin names and major common names) Each monograph includes the following information: Alternative common names Active ingredients Uses – both traditional and modern Adverse effects References Drug names are designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names or brand names are used. The material is drawn from the fifteenth edition of the internationally renowned encyclopedia, Meyler’s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. This volume is critical for any health professional or homeopathic practitioner with an interest in herbal medicines.

Related subjects